Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults

This trial explores how trigonelline monohydrate affects NAD+ metabolism in generally healthy adults. NAD+ plays a crucial role in cellular energy production, and the study aims to determine how different doses of trigonelline influence its blood levels. Participants will receive either trigonelline monohydrate, a comparison treatment called nicotinamide mononucleotide (NMN), or a placebo for four weeks. Individuals who are healthy, non-smokers, and maintain stable dietary habits may be suitable candidates. The trial will also assess safety and how the body processes these supplements. As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, offering participants a chance to be among the first to receive this new treatment.

Research has shown that trigonelline, a compound found in coffee and other plants, is generally safe for humans. Although few studies focus specifically on trigonelline monohydrate, similar compounds that increase NAD+ levels, such as NMN, have proven safe in early research. People taking NAD+ boosters, like NMN, usually experience few side effects. However, those with cancer concerns should exercise caution, as NAD+ boosters can influence cell growth.

Studies on nicotinamide mononucleotide (NMN) have demonstrated its safety for short-term use in humans, with only mild side effects like stomach discomfort. In this trial, NMN serves as a comparison to help assess the safety of trigonelline monohydrate.

Researchers are excited about Trigonelline Monohydrate and Nicotinamide Mononucleotide (NMN) because they offer a fresh approach to boosting NAD+ metabolism, which is crucial for energy production and cellular health. Unlike many existing supplements that rely on indirect methods to enhance NAD+ levels, Trigonelline Monohydrate is a direct precursor that might efficiently elevate NAD+ levels. NMN, on the other hand, is already known for its role in stimulating NAD+ production, but pairing it with Trigonelline Monohydrate could potentially amplify its effects. These treatments could offer a more potent and direct way to support cellular health compared to traditional options.

This trial will compare the effects of Trigonelline Monohydrate and Nicotinamide Mononucleotide (NMN) on NAD+ metabolism in healthy adults. Research has shown that trigonelline could effectively boost NAD+, a molecule crucial for energy and cell health. In animal studies, trigonelline improved muscle strength and reduced tiredness as the animals aged, suggesting it might help increase NAD+ levels, which are vital for maintaining energy and reducing signs of aging. Similarly, NMN, another NAD+ booster tested in this trial, has been safely processed by the body and may help with age-related issues by raising NAD+ levels. Both treatments have shown potential benefits in early studies, but more research with humans is needed to confirm their effects.⁶⁷⁸⁹¹⁰